nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—pancreatitis	0.66	1	CbGaD
Lenalidomide—CDH5—Cell-cell junction organization—CLDN2—pancreatitis	0.0138	0.111	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CLDN2—pancreatitis	0.0104	0.0836	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—SPP1—pancreatitis	0.00999	0.08	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—FGG—pancreatitis	0.00881	0.0706	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—A2M—pancreatitis	0.00819	0.0656	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—CLDN2—pancreatitis	0.00743	0.0595	CbGpPWpGaD
Lenalidomide—Dermatitis atopic—Propantheline—pancreatitis	0.00613	0.0345	CcSEcCtD
Lenalidomide—Arrhythmia supraventricular—Hyoscyamine—pancreatitis	0.00599	0.0337	CcSEcCtD
Lenalidomide—Rash macular—Hyoscyamine—pancreatitis	0.00566	0.0319	CcSEcCtD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—HSP90AB1—pancreatitis	0.00507	0.0406	CbGpPWpGaD
Lenalidomide—Loss of libido—Hyoscyamine—pancreatitis	0.00503	0.0283	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—PDGFA—pancreatitis	0.00493	0.0395	CbGpPWpGaD
Lenalidomide—TNFSF11—blood—pancreatitis	0.00483	0.18	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—HGF—pancreatitis	0.00446	0.0357	CbGpPWpGaD
Lenalidomide—Pomalidomide—TNF—pancreatitis	0.00426	0.412	CrCbGaD
Lenalidomide—Blindness—Hyoscyamine—pancreatitis	0.00419	0.0236	CcSEcCtD
Lenalidomide—CRBN—islet of Langerhans—pancreatitis	0.00403	0.15	CbGeAlD
Lenalidomide—Visual acuity reduced—Hyoscyamine—pancreatitis	0.0039	0.022	CcSEcCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—CRP—pancreatitis	0.00382	0.0306	CbGpPWpGaD
Lenalidomide—CDH5—blood—pancreatitis	0.00363	0.135	CbGeAlD
Lenalidomide—Supraventricular tachycardia—Hyoscyamine—pancreatitis	0.00354	0.02	CcSEcCtD
Lenalidomide—Haemoglobin decreased—Hyoscyamine—pancreatitis	0.00337	0.019	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—INS—pancreatitis	0.00314	0.0251	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—ICAM1—pancreatitis	0.00309	0.0248	CbGpPWpGaD
Lenalidomide—Rash erythematous—Hyoscyamine—pancreatitis	0.00303	0.0171	CcSEcCtD
Lenalidomide—Ageusia—Hyoscyamine—pancreatitis	0.00287	0.0161	CcSEcCtD
Lenalidomide—Abdominal distension—Propantheline—pancreatitis	0.00286	0.0161	CcSEcCtD
Lenalidomide—Dysphagia—Propantheline—pancreatitis	0.00285	0.016	CcSEcCtD
Lenalidomide—CRBN—pancreas—pancreatitis	0.00283	0.106	CbGeAlD
Lenalidomide—Petechiae—Hyoscyamine—pancreatitis	0.00282	0.0159	CcSEcCtD
Lenalidomide—Thalidomide—TNF—pancreatitis	0.00274	0.266	CrCbGaD
Lenalidomide—Speech disorder—Hyoscyamine—pancreatitis	0.0027	0.0152	CcSEcCtD
Lenalidomide—Erectile dysfunction—Propantheline—pancreatitis	0.00262	0.0148	CcSEcCtD
Lenalidomide—Ventricular extrasystoles—Hyoscyamine—pancreatitis	0.00257	0.0145	CcSEcCtD
Lenalidomide—Gastrooesophageal reflux disease—Hyoscyamine—pancreatitis	0.00257	0.0145	CcSEcCtD
Lenalidomide—Dysarthria—Hyoscyamine—pancreatitis	0.00245	0.0138	CcSEcCtD
Lenalidomide—CRBN—digestive system—pancreatitis	0.00242	0.0902	CbGeAlD
Lenalidomide—Respiratory failure—Hyoscyamine—pancreatitis	0.00236	0.0133	CcSEcCtD
Lenalidomide—CRBN—blood—pancreatitis	0.00231	0.086	CbGeAlD
Lenalidomide—Depressed level of consciousness—Hyoscyamine—pancreatitis	0.00224	0.0126	CcSEcCtD
Lenalidomide—Dry eye—Hyoscyamine—pancreatitis	0.00214	0.0121	CcSEcCtD
Lenalidomide—Flushing—Propantheline—pancreatitis	0.00211	0.0119	CcSEcCtD
Lenalidomide—Pulmonary oedema—Hyoscyamine—pancreatitis	0.00207	0.0116	CcSEcCtD
Lenalidomide—Pomalidomide—PTGS2—pancreatitis	0.00202	0.196	CrCbGaD
Lenalidomide—Tension—Propantheline—pancreatitis	0.00195	0.011	CcSEcCtD
Lenalidomide—Nervousness—Propantheline—pancreatitis	0.00193	0.0108	CcSEcCtD
Lenalidomide—Eczema—Hyoscyamine—pancreatitis	0.00188	0.0106	CcSEcCtD
Lenalidomide—Vision blurred—Propantheline—pancreatitis	0.00187	0.0105	CcSEcCtD
Lenalidomide—Nasal congestion—Hyoscyamine—pancreatitis	0.00185	0.0104	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB1—pancreatitis	0.00182	0.0146	CbGpPWpGaD
Lenalidomide—Atrial fibrillation—Hyoscyamine—pancreatitis	0.00178	0.01	CcSEcCtD
Lenalidomide—Palpitations—Propantheline—pancreatitis	0.00175	0.00987	CcSEcCtD
Lenalidomide—Hypoglycaemia—Hyoscyamine—pancreatitis	0.00173	0.00973	CcSEcCtD
Lenalidomide—Lethargy—Hyoscyamine—pancreatitis	0.00172	0.00969	CcSEcCtD
Lenalidomide—Hyponatraemia—Hyoscyamine—pancreatitis	0.00169	0.00953	CcSEcCtD
Lenalidomide—Osteoarthritis—Hyoscyamine—pancreatitis	0.00169	0.00949	CcSEcCtD
Lenalidomide—PTGS2—gall bladder—pancreatitis	0.00168	0.0624	CbGeAlD
Lenalidomide—Dry mouth—Propantheline—pancreatitis	0.00165	0.0093	CcSEcCtD
Lenalidomide—Confusional state—Propantheline—pancreatitis	0.00163	0.00919	CcSEcCtD
Lenalidomide—Urinary retention—Hyoscyamine—pancreatitis	0.0016	0.00903	CcSEcCtD
Lenalidomide—Cardiac arrest—Hyoscyamine—pancreatitis	0.0016	0.00903	CcSEcCtD
Lenalidomide—Ataxia—Hyoscyamine—pancreatitis	0.00158	0.00893	CcSEcCtD
Lenalidomide—Tachycardia—Propantheline—pancreatitis	0.00158	0.0089	CcSEcCtD
Lenalidomide—Dehydration—Hyoscyamine—pancreatitis	0.00157	0.00883	CcSEcCtD
Lenalidomide—Dry skin—Hyoscyamine—pancreatitis	0.00154	0.0087	CcSEcCtD
Lenalidomide—Hypokalaemia—Hyoscyamine—pancreatitis	0.00153	0.00864	CcSEcCtD
Lenalidomide—ABCB1—ABC-family proteins mediated transport—CFTR—pancreatitis	0.0015	0.0121	CbGpPWpGaD
Lenalidomide—Abdominal distension—Hyoscyamine—pancreatitis	0.00147	0.00826	CcSEcCtD
Lenalidomide—Insomnia—Propantheline—pancreatitis	0.00146	0.00824	CcSEcCtD
Lenalidomide—Dysphagia—Hyoscyamine—pancreatitis	0.00146	0.0082	CcSEcCtD
Lenalidomide—Somnolence—Propantheline—pancreatitis	0.00144	0.0081	CcSEcCtD
Lenalidomide—Angina pectoris—Hyoscyamine—pancreatitis	0.00142	0.00799	CcSEcCtD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—pancreatitis	0.00139	0.0112	CbGpPWpGaD
Lenalidomide—Constipation—Propantheline—pancreatitis	0.00138	0.00779	CcSEcCtD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—pancreatitis	0.00137	0.011	CbGpPWpGaD
Lenalidomide—Dysuria—Hyoscyamine—pancreatitis	0.00136	0.00767	CcSEcCtD
Lenalidomide—Erectile dysfunction—Hyoscyamine—pancreatitis	0.00134	0.00756	CcSEcCtD
Lenalidomide—Feeling abnormal—Propantheline—pancreatitis	0.00133	0.00751	CcSEcCtD
Lenalidomide—Hyperglycaemia—Hyoscyamine—pancreatitis	0.00131	0.0074	CcSEcCtD
Lenalidomide—Thalidomide—PTGS2—pancreatitis	0.0013	0.126	CrCbGaD
Lenalidomide—Depression—Hyoscyamine—pancreatitis	0.0013	0.00729	CcSEcCtD
Lenalidomide—Urticaria—Propantheline—pancreatitis	0.00129	0.00724	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Hyoscyamine—pancreatitis	0.00128	0.00721	CcSEcCtD
Lenalidomide—Myocardial infarction—Hyoscyamine—pancreatitis	0.00127	0.00717	CcSEcCtD
Lenalidomide—Conjunctivitis—Hyoscyamine—pancreatitis	0.00126	0.00711	CcSEcCtD
Lenalidomide—Sweating—Hyoscyamine—pancreatitis	0.00125	0.00701	CcSEcCtD
Lenalidomide—Hypersensitivity—Propantheline—pancreatitis	0.00119	0.00672	CcSEcCtD
Lenalidomide—Bradycardia—Hyoscyamine—pancreatitis	0.00119	0.00669	CcSEcCtD
Lenalidomide—Asthenia—Propantheline—pancreatitis	0.00116	0.00654	CcSEcCtD
Lenalidomide—Hallucination—Hyoscyamine—pancreatitis	0.00116	0.00653	CcSEcCtD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—CTRB2—pancreatitis	0.00111	0.00885	CbGpPWpGaD
Lenalidomide—PTGS2—islet of Langerhans—pancreatitis	0.0011	0.0409	CbGeAlD
Lenalidomide—Flushing—Hyoscyamine—pancreatitis	0.00108	0.00609	CcSEcCtD
Lenalidomide—Dizziness—Propantheline—pancreatitis	0.00107	0.00603	CcSEcCtD
Lenalidomide—Arrhythmia—Hyoscyamine—pancreatitis	0.00104	0.00587	CcSEcCtD
Lenalidomide—Vomiting—Propantheline—pancreatitis	0.00103	0.0058	CcSEcCtD
Lenalidomide—Mental disorder—Hyoscyamine—pancreatitis	0.00102	0.00575	CcSEcCtD
Lenalidomide—Rash—Propantheline—pancreatitis	0.00102	0.00575	CcSEcCtD
Lenalidomide—Dermatitis—Propantheline—pancreatitis	0.00102	0.00574	CcSEcCtD
Lenalidomide—Erythema—Hyoscyamine—pancreatitis	0.00101	0.00572	CcSEcCtD
Lenalidomide—Headache—Propantheline—pancreatitis	0.00101	0.00571	CcSEcCtD
Lenalidomide—Tension—Hyoscyamine—pancreatitis	0.000996	0.00561	CcSEcCtD
Lenalidomide—Dysgeusia—Hyoscyamine—pancreatitis	0.000994	0.0056	CcSEcCtD
Lenalidomide—Nervousness—Hyoscyamine—pancreatitis	0.000986	0.00555	CcSEcCtD
Lenalidomide—Nausea—Propantheline—pancreatitis	0.000961	0.00541	CcSEcCtD
Lenalidomide—Vision blurred—Hyoscyamine—pancreatitis	0.000957	0.00539	CcSEcCtD
Lenalidomide—Agitation—Hyoscyamine—pancreatitis	0.000933	0.00525	CcSEcCtD
Lenalidomide—Angioedema—Hyoscyamine—pancreatitis	0.000927	0.00522	CcSEcCtD
Lenalidomide—Vertigo—Hyoscyamine—pancreatitis	0.000912	0.00514	CcSEcCtD
Lenalidomide—Syncope—Hyoscyamine—pancreatitis	0.00091	0.00513	CcSEcCtD
Lenalidomide—Palpitations—Hyoscyamine—pancreatitis	0.000897	0.00505	CcSEcCtD
Lenalidomide—Loss of consciousness—Hyoscyamine—pancreatitis	0.000892	0.00502	CcSEcCtD
Lenalidomide—Chest pain—Hyoscyamine—pancreatitis	0.000864	0.00487	CcSEcCtD
Lenalidomide—Anxiety—Hyoscyamine—pancreatitis	0.000861	0.00485	CcSEcCtD
Lenalidomide—Dry mouth—Hyoscyamine—pancreatitis	0.000845	0.00476	CcSEcCtD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS1—pancreatitis	0.000837	0.00671	CbGpPWpGaD
Lenalidomide—Confusional state—Hyoscyamine—pancreatitis	0.000835	0.0047	CcSEcCtD
Lenalidomide—Oedema—Hyoscyamine—pancreatitis	0.000828	0.00467	CcSEcCtD
Lenalidomide—Shock—Hyoscyamine—pancreatitis	0.000815	0.00459	CcSEcCtD
Lenalidomide—Tachycardia—Hyoscyamine—pancreatitis	0.000808	0.00455	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CRP—pancreatitis	0.000805	0.00645	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Hyoscyamine—pancreatitis	0.000801	0.00451	CcSEcCtD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—pancreatitis	0.000794	0.00636	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NRAS—pancreatitis	0.000781	0.00626	CbGpPWpGaD
Lenalidomide—Hypotension—Hyoscyamine—pancreatitis	0.000774	0.00436	CcSEcCtD
Lenalidomide—PTGS2—pancreas—pancreatitis	0.000772	0.0288	CbGeAlD
Lenalidomide—Insomnia—Hyoscyamine—pancreatitis	0.000749	0.00422	CcSEcCtD
Lenalidomide—Dyspnoea—Hyoscyamine—pancreatitis	0.000739	0.00416	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—NRAS—pancreatitis	0.000737	0.00591	CbGpPWpGaD
Lenalidomide—Somnolence—Hyoscyamine—pancreatitis	0.000736	0.00415	CcSEcCtD
Lenalidomide—Dyspepsia—Hyoscyamine—pancreatitis	0.000729	0.00411	CcSEcCtD
Lenalidomide—Fatigue—Hyoscyamine—pancreatitis	0.000714	0.00402	CcSEcCtD
Lenalidomide—Constipation—Hyoscyamine—pancreatitis	0.000708	0.00399	CcSEcCtD
Lenalidomide—Pain—Hyoscyamine—pancreatitis	0.000708	0.00399	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—XDH—pancreatitis	0.000706	0.00565	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Hyoscyamine—pancreatitis	0.000683	0.00384	CcSEcCtD
Lenalidomide—ABCB1—islet of Langerhans—pancreatitis	0.000679	0.0253	CbGeAlD
Lenalidomide—Gastrointestinal pain—Hyoscyamine—pancreatitis	0.000677	0.00382	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—KRAS—pancreatitis	0.000672	0.00539	CbGpPWpGaD
Lenalidomide—PTGS2—digestive system—pancreatitis	0.000659	0.0246	CbGeAlD
Lenalidomide—Urticaria—Hyoscyamine—pancreatitis	0.000658	0.00371	CcSEcCtD
Lenalidomide—Body temperature increased—Hyoscyamine—pancreatitis	0.000655	0.00369	CcSEcCtD
Lenalidomide—Abdominal pain—Hyoscyamine—pancreatitis	0.000655	0.00369	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—KRAS—pancreatitis	0.000635	0.00508	CbGpPWpGaD
Lenalidomide—PTGS2—blood—pancreatitis	0.000628	0.0234	CbGeAlD
Lenalidomide—Hypersensitivity—Hyoscyamine—pancreatitis	0.00061	0.00344	CcSEcCtD
Lenalidomide—Asthenia—Hyoscyamine—pancreatitis	0.000594	0.00335	CcSEcCtD
Lenalidomide—Pruritus—Hyoscyamine—pancreatitis	0.000586	0.0033	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—pancreatitis	0.000571	0.00458	CbGpPWpGaD
Lenalidomide—Diarrhoea—Hyoscyamine—pancreatitis	0.000567	0.00319	CcSEcCtD
Lenalidomide—Dizziness—Hyoscyamine—pancreatitis	0.000548	0.00309	CcSEcCtD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—pancreatitis	0.000547	0.00438	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—pancreatitis	0.000539	0.00432	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—EGR1—pancreatitis	0.000535	0.00429	CbGpPWpGaD
Lenalidomide—Vomiting—Hyoscyamine—pancreatitis	0.000527	0.00297	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—pancreatitis	0.000524	0.00419	CbGpPWpGaD
Lenalidomide—Rash—Hyoscyamine—pancreatitis	0.000522	0.00294	CcSEcCtD
Lenalidomide—Dermatitis—Hyoscyamine—pancreatitis	0.000522	0.00294	CcSEcCtD
Lenalidomide—Headache—Hyoscyamine—pancreatitis	0.000519	0.00292	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—IL6—pancreatitis	0.000516	0.00414	CbGpPWpGaD
Lenalidomide—Nausea—Hyoscyamine—pancreatitis	0.000492	0.00277	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PNLIP—pancreatitis	0.000488	0.00391	CbGpPWpGaD
Lenalidomide—ABCB1—pancreas—pancreatitis	0.000477	0.0178	CbGeAlD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP12—pancreatitis	0.000475	0.0038	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MPO—pancreatitis	0.000466	0.00373	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—LPL—pancreatitis	0.000463	0.00371	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MPO—pancreatitis	0.000449	0.0036	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PPY—pancreatitis	0.000438	0.00351	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—PPP3CA—pancreatitis	0.000427	0.00342	CbGpPWpGaD
Lenalidomide—ABCB1—digestive system—pancreatitis	0.000408	0.0152	CbGeAlD
Lenalidomide—PTGS2—Spinal Cord Injury—TACR1—pancreatitis	0.000401	0.00321	CbGpPWpGaD
Lenalidomide—ABCB1—blood—pancreatitis	0.000388	0.0145	CbGeAlD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—pancreatitis	0.000364	0.00292	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL13—pancreatitis	0.000347	0.00278	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGG—pancreatitis	0.000338	0.00271	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SCT—pancreatitis	0.000338	0.00271	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASR—pancreatitis	0.000338	0.00271	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP12—pancreatitis	0.000337	0.0027	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CX3CL1—pancreatitis	0.000332	0.00266	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—PPP3CA—pancreatitis	0.000325	0.00261	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCK—pancreatitis	0.000323	0.00258	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MTNR1B—pancreatitis	0.000323	0.00258	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—pancreatitis	0.000316	0.00254	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TACR1—pancreatitis	0.000314	0.00252	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—A2M—pancreatitis	0.000314	0.00252	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CNR2—pancreatitis	0.000314	0.00252	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCKAR—pancreatitis	0.000309	0.00248	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatitis	0.000305	0.00245	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—HSP90AB1—pancreatitis	0.000299	0.0024	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—pancreatitis	0.000294	0.00236	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGA—pancreatitis	0.000288	0.0023	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGR1—pancreatitis	0.000269	0.00216	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTHLH—pancreatitis	0.000267	0.00214	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SMO—pancreatitis	0.000267	0.00214	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGB—pancreatitis	0.000262	0.0021	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PPP3CA—pancreatitis	0.000255	0.00204	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DQA1—pancreatitis	0.000246	0.00197	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SST—pancreatitis	0.000244	0.00196	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—DUSP6—pancreatitis	0.000242	0.00194	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—pancreatitis	0.000241	0.00193	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CRP—pancreatitis	0.000236	0.00189	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—pancreatitis	0.000232	0.00186	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—pancreatitis	0.000231	0.00185	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—BDKRB2—pancreatitis	0.00023	0.00184	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CNR1—pancreatitis	0.000226	0.00181	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GCG—pancreatitis	0.000218	0.00175	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—pancreatitis	0.000217	0.00174	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL10—pancreatitis	0.000217	0.00174	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—FDX1—pancreatitis	0.000213	0.00171	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—HSP90AB1—pancreatitis	0.000212	0.0017	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KNG1—pancreatitis	0.000209	0.00168	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—pancreatitis	0.000207	0.00166	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—pancreatitis	0.000206	0.00165	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—INS—pancreatitis	0.000197	0.00158	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CCL2—pancreatitis	0.000194	0.00156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PDGFA—pancreatitis	0.000192	0.00154	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGR1—pancreatitis	0.000183	0.00147	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—LEP—pancreatitis	0.000183	0.00146	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ALB—pancreatitis	0.000181	0.00145	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—pancreatitis	0.00018	0.00144	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TLR4—pancreatitis	0.000179	0.00143	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—pancreatitis	0.000178	0.00143	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PNLIP—pancreatitis	0.000177	0.00142	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL5—pancreatitis	0.000175	0.0014	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—HLA-DRB1—pancreatitis	0.000175	0.0014	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—ICAM1—pancreatitis	0.000172	0.00138	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LPL—pancreatitis	0.000171	0.00137	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—pancreatitis	0.000168	0.00135	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFA—pancreatitis	0.000167	0.00134	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—pancreatitis	0.000164	0.00132	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SPP1—pancreatitis	0.000162	0.0013	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CFTR—pancreatitis	0.000157	0.00126	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HTR2A—pancreatitis	0.000154	0.00124	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCL2—pancreatitis	0.000154	0.00123	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—pancreatitis	0.000151	0.00121	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL1B—pancreatitis	0.000147	0.00118	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—LEP—pancreatitis	0.000143	0.00115	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTRB2—pancreatitis	0.000131	0.00105	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—pancreatitis	0.00013	0.00104	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—NRAS—pancreatitis	0.000128	0.00102	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—INS—pancreatitis	0.000122	0.000981	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—pancreatitis	0.000121	0.000973	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCL2—pancreatitis	0.00012	0.000965	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—pancreatitis	0.000119	0.000951	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFA—pancreatitis	0.000118	0.000947	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PLA2G1B—pancreatitis	0.000118	0.000945	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1B—pancreatitis	0.000117	0.000933	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—pancreatitis	0.000116	0.000931	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—A2M—pancreatitis	0.000114	0.000912	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL1B—pancreatitis	0.000114	0.000912	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—pancreatitis	0.000114	0.00091	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—pancreatitis	0.00011	0.000882	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CTRB2—pancreatitis	0.00011	0.000878	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—pancreatitis	0.000107	0.000857	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MDM2—pancreatitis	0.000102	0.000816	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRSS1—pancreatitis	9.91e-05	0.000794	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—pancreatitis	9.52e-05	0.000763	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—FDX1—pancreatitis	9.5e-05	0.000761	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PNLIP—pancreatitis	9.4e-05	0.000753	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRSS3—pancreatitis	9.4e-05	0.000753	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—pancreatitis	9.36e-05	0.00075	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TRPV1—pancreatitis	9.26e-05	0.000742	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP3—pancreatitis	9.12e-05	0.00073	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—pancreatitis	9.05e-05	0.000725	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—pancreatitis	8.85e-05	0.000709	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—pancreatitis	8.84e-05	0.000708	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ADH4—pancreatitis	8.83e-05	0.000707	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—pancreatitis	8.63e-05	0.000691	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—pancreatitis	8.46e-05	0.000677	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—LTF—pancreatitis	8.43e-05	0.000675	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PRSS1—pancreatitis	8.3e-05	0.000665	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—pancreatitis	8.26e-05	0.000662	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—pancreatitis	7.91e-05	0.000634	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PNLIP—pancreatitis	7.87e-05	0.000631	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PRSS3—pancreatitis	7.87e-05	0.000631	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CTRB2—pancreatitis	7.77e-05	0.000622	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NRAS—pancreatitis	7.64e-05	0.000612	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—pancreatitis	7.1e-05	0.000569	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—XDH—pancreatitis	7.06e-05	0.000566	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—pancreatitis	6.82e-05	0.000547	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FDX1—pancreatitis	6.73e-05	0.000539	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ADH1B—pancreatitis	6.58e-05	0.000527	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—pancreatitis	6.58e-05	0.000527	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—pancreatitis	6.26e-05	0.000502	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ADH4—pancreatitis	6.26e-05	0.000501	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—LPL—pancreatitis	6.19e-05	0.000496	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatitis	6.16e-05	0.000493	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatitis	6.04e-05	0.000484	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PRSS1—pancreatitis	5.89e-05	0.000472	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—pancreatitis	5.75e-05	0.000461	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—pancreatitis	5.71e-05	0.000457	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—pancreatitis	5.61e-05	0.000449	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—pancreatitis	5.59e-05	0.000448	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PNLIP—pancreatitis	5.58e-05	0.000447	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PRSS3—pancreatitis	5.58e-05	0.000447	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGA—pancreatitis	5.54e-05	0.000444	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—pancreatitis	5.35e-05	0.000429	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLA2G1B—pancreatitis	5.25e-05	0.000421	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—A2M—pancreatitis	5.07e-05	0.000406	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—XDH—pancreatitis	5e-05	0.000401	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PPP3CA—pancreatitis	4.91e-05	0.000394	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ADH1B—pancreatitis	4.67e-05	0.000374	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALDH2—pancreatitis	4.64e-05	0.000372	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—pancreatitis	4.52e-05	0.000362	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatitis	4.37e-05	0.00035	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatitis	4.08e-05	0.000327	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—pancreatitis	4.07e-05	0.000326	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatitis	4.04e-05	0.000324	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLA2G1B—pancreatitis	3.72e-05	0.000298	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFA—pancreatitis	3.7e-05	0.000297	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—A2M—pancreatitis	3.6e-05	0.000288	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GCG—pancreatitis	3.52e-05	0.000282	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—LPL—pancreatitis	3.29e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDH2—pancreatitis	3.29e-05	0.000263	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LPL—pancreatitis	2.76e-05	0.000221	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—pancreatitis	2.74e-05	0.00022	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GCG—pancreatitis	2.49e-05	0.0002	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—INS—pancreatitis	2.36e-05	0.000189	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—pancreatitis	2.01e-05	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—INS—pancreatitis	1.98e-05	0.000158	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MDM2—pancreatitis	1.96e-05	0.000157	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LPL—pancreatitis	1.96e-05	0.000157	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—pancreatitis	1.81e-05	0.000145	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—pancreatitis	1.47e-05	0.000118	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—pancreatitis	1.43e-05	0.000114	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—INS—pancreatitis	1.4e-05	0.000112	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—pancreatitis	1.37e-05	0.00011	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—pancreatitis	1.28e-05	0.000103	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—pancreatitis	1.27e-05	0.000101	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—pancreatitis	1.12e-05	9e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—pancreatitis	1.08e-05	8.63e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—pancreatitis	1.03e-05	8.26e-05	CbGpPWpGaD
